Key facts
- This page summarizes Keith Crandell's Form 4 filing for Sana Biotechnology, Inc. (SANA).
- 3 reported transactions and 0 derivative rows are listed below.
- Accepted by SEC: 12 Feb 2024, 17:43.
Keith Crandell - 08 Feb 2024 Form 4 Insider Report for Sana Biotechnology, Inc. (SANA)
- Reporting relationship
- 10%+ Owner
- Issuer ticker
- SANA
- Reported as of
- 08 Feb 2024
- Net transaction value
- +$9,999,996
- SEC form
- 4
- Accepted by SEC
- 12 Feb 2024, 17:43:56 UTC
- Prior SEC filing
- 09 Feb 2024
- Next SEC filing
- 27 Mar 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Keith Crandell, By: Mark McDonnell, attorney in-fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Keith Crandell filed Form 4 for Sana Biotechnology, Inc. (SANA) on 12 Feb 2024.
Change
- Previous filing in this sequence was filed on 09 Feb 2024.
- Current net transaction value: +$9,999,996.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
SANA
transaction
Common Stock
Purchase
- Transaction value
- $2,000,004
- Shares
- +363,637
- Change %
- +3.5%
- Price
- $5.50
- Shares after
- 10,667,387
- Date
- 08 Feb 2024
- Ownership
- See Footnote
- Footnotes
- F1, F3
SANA
transaction
Common Stock
Purchase
- Transaction value
- $3,999,996
- Shares
- +727,272
- Change %
- +6.2%
- Price
- $5.50
- Shares after
- 12,446,022
- Date
- 08 Feb 2024
- Ownership
- See Footnote
- Footnotes
- F4, F6
SANA
transaction
Common Stock
Purchase
- Transaction value
- $3,999,996
- Shares
- +727,272
- Change %
- +6.2%
- Price
- $5.50
- Shares after
- 12,446,022
- Date
- 08 Feb 2024
- Ownership
- See Footnote
- Footnotes
- F5, F6
SANA
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 10,301,250
- Date
- 08 Feb 2024
- Ownership
- See Footnote
- Footnotes
- F2, F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 6 footnotes
Footnote F1
Represents shares held directly by ARCH Venture Fund IX, L.P. (ARCH IX). ARCH Venture Partners IX, L.P. (AVP IX LP) is the sole general partner of ARCH IX.
Footnote F2
Represents shares held directly by ARCH Venture Fund IX Overage, L.P. (ARCH IX Overage). ARCH Venture Partners IX Overage, L.P. (AVP IX Overage LP) is the sole general partner of ARCH IX Overage.
Footnote F3
ARCH Venture Partners IX, LLC (AVP IX LLC) is the sole general partner of each of AVP IX LP and AVP IX Overage LP. Keith Crandell and Clinton Bybee are managing directors of AVP IX LLC (the AVP IX MDs). AVP IX LP and AVP IX Overage LP may be deemed to beneficially own the shares held by ARCH IX and ARCH IX Overage, respectively, AVP IX LLC may be deemed to beneficially own the shares held by ARCH IX and ARCH IX Overage, and each of the AVP IX MDs may be deemed to share the power to direct the disposition and vote of the shares held by ARCH IX and ARCH IX Overage. AVP IX LP, AVP IX Overage LP, AVP IX LLC, and the AVP IX MDs each disclaim beneficial ownership except to to the extent of any pecuniary interest therein.
Footnote F4
Represents shares held directly by ARCH Venture Fund X, L.P. (ARCH X). ARCH Venture Partners X, L.P. (AVP X LP) is the sole general partner of ARCH X.
Footnote F5
Represents shares held directly by ARCH Venture Fund X Overage, L.P. (ARCH X Overage). ARCH Venture Partners X Overage, L.P. (AVP X Overage LP) is the sole general partner of ARCH X Overage.
Footnote F6
ARCH Venture Partners X, LLC (AVP X LLC) is the sole general partner of each of AVP X LP and AVP X Overage LP. Keith Crandell, Kristina Burow and Steven Gillis are members of the investment committee of AVP X LLC (the AVP X Committee Members). AVP X LP and AVP X Overage LP may be deemed to beneficially own the shares held by ARCH X and ARCH X Overage, respectively, AVP X LLC may be deemed to beneficially own the shares held by ARCH X and ARCH X Overage, and each of the AVP X Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH X and ARCH X Overage. AVP X LP, AVP X Overage LP, AVP X LLC, and the AVP X Committee Members each disclaim beneficial ownership except to the extent of any pecuniary interest therein.
SEC remarks
This Form 4 is one of two reports relating to the same transaction being filed jointly by ARCH IX, AVP IX LP, ARCH IX Overage, AVP IX Overage LP, AVP IX LLC, ARCH X, AVP X LP, ARCH X Overage, AVP X Overage LP, AVP X LLC, Keith Crandell, Clinton Bybee, Kristina Burow and Steven Gillis (collectively, the "Reporting Persons"). Robert Nelsen has direct ownership of Common Stock and is filing his own Form 4 separately.